KRT18 and metabolic dysfunction-associated steatohepatitis: Since Feldstein et al71 first reported that serum CK-18 levels could predict NASH, a few studies with small population samples have confirmed these findings.72, 73, 74 However, CK-18 has limitations, including the lack of clinical trials with high levels of evidence, and its sensitivity and specificity are limited at the individual level.